Spinal Muscular Atrophy Pipeline Drugs Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
"Spinal Muscular Atrophy Pipeline"
Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals, CANbridge Pharmaceuticals Inc., Astellas Pharma, Alcyone Therapeutics, Exicure, AndroScience Corporation, Scholar Rock, NMD Pharma, Aurimed Pharma, Biogen, Hanugen Theraputics, and others.
(Albany, USA) 'Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.
The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:
In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA
Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment
Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®).
On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C).
On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®).
On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study.
On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA)
Spinal Muscular Atrophy Overview
Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression.
Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening.
Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life.
Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA.
Spinal Muscular Atrophy Pipeline Therapeutics Assessment
DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:
ACTX-401: Novartis
Apitegromab: Scholar Rock
GYM329: Roche
And Many Others
Spinal Muscular Atrophy Pipeline Analysis:
The Spinal Muscular Atrophy pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs
Scope of Spinal Muscular Atrophy Pipeline Drug Insight
Coverage: Global
Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others
Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers
Table of Contents
Spinal Muscular Atrophy Report Introduction
Spinal Muscular Atrophy Executive Summary
Spinal Muscular Atrophy Overview
Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
Spinal Muscular Atrophy Pipeline Therapeutics
Spinal Muscular Atrophy Late Stage Products (Phase II/III)
Spinal Muscular Atrophy Mid Stage Products (Phase II)
Spinal Muscular Atrophy Early Stage Products (Phase I)
Spinal Muscular Atrophy Preclinical Stage Products
Spinal Muscular Atrophy Therapeutics Assessment
Spinal Muscular Atrophy Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Spinal Muscular Atrophy Key Companies
Spinal Muscular Atrophy Key Products
Spinal Muscular Atrophy Unmet Needs
Spinal Muscular Atrophy Market Drivers and Barriers
Spinal Muscular Atrophy Future Perspectives and Conclusion
Spinal Muscular Atrophy Analyst Views
Appendix
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Canada Post rejects union terms for arbitration as both sides enter bitter stalemate
Canadian Union of Postal Workers (CUPW) President Jan Simpson, second from right, takes part in a Canada Post rally outside of the Prime Minister's Office in Ottawa, on Saturday. Photo by Spencer Colby / Postmedia MONTREAL — A government push to steer Canada Post and the union representing 55,000 mail workers toward common ground hit a big pothole Monday. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors As an increasingly acrimonious impasse drags on, Canada Post rejected a framework put forward by the union for a binding arbitration process, which Jobs Minister Patty Hajdu asked the parties to work toward just five days earlier. Canada Post spokeswoman Lisa Liu said the Canadian Union of Postal Workers has effectively refused to take heed of a federally commissioned report that called for major reforms to the 158-year-old institution, including more flexible routes and part-time weekend positions with similar pay rates and benefits. Get a dash of perspective along with the trending news of the day in a very readable format. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again 'The union's refusal to recognize the IIC (industrial inquiry commission) report and its recommendations in their proposed terms of reference for arbitration is unacceptable,' she said in a statement. The Canadian Union of Postal Workers said its goal remains a return to the bargaining table to hammer out a new contract. 'However, Canada Post's actions suggest it does not want to negotiate. It wants to rewrite our agreements — and is seeking to use government interference to further its goals,' the union said in a release Monday. Canada Post questioned that claim, noting that the union has not responded to its latest offer from May 28. The two sides exchanged some information on Thursday and Friday through federal mediators, but have had little contact since, the Crown corporation added. Meanwhile, the union called on members to sign a letter to the minister opposing the prospect of a forced vote on Canada Post's 'final offers.' The letter says that such a move — requested by Canada Post _ would amount to government interference, tip the scales in the employer's favour and potentially sow division in the ranks of employees. 'The issues will remain contentious among some, most or all of the membership, depending upon how the vote goes,' the Sunday missive states, adding that resulting resentment would undermine labour peace. Union president Jan Simpson hinted at possible rifts within the membership last week, saying in an update that 'although tensions are high, let's not forget our fight is with the employer, not one another.' Canada Post's last proposal includes an end to compulsory overtime, signing bonuses of between $500 and $1,000 and cost-of-living payments that are triggered at a lower inflation threshold.
Globe and Mail
an hour ago
- Globe and Mail
Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
"Obesity Drugs Market" Obesity Companies such as Yuhan, Click Therapeutics, Novo Nordisk, ProQR Therapeutics, Bukwang Pharmaceutical, Empros Pharma, Boehringer Ingelhium, Rhythm Pharmaceuticals, BioRestorative Therapies, Hanmi Pharmaceuticals, Carmot Therapeutics, D&D Pharmatech, SCOHIA PHARMA, Nano Precision Medical, Terns Pharmaceuticals, Caliway Biopharmaceutics, Eli Lilly and Company, and others (Albany, USA) DelveInsight's 'Obesity Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market. Request for a Free Sample Report @ Obesity Market Forecast Some facts of the Obesity Market Report are: In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand. In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance. In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action. In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly's rival GLP-1 drug Zepbound may still have an advantage over Wegovy. In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly's reply due by January 21. As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023. DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023. According to the findings, treatment rate for children was found to be less than that of adults across countries. Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany. The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others. On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments. On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity. Obesity Overview Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens. Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Obesity Market The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034. Obesity Epidemiology The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions. Explore more about Obesity Epidemiology @ Obesity Market Dynamics Obesity Drugs Uptake This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Obesity Pipeline Development Activities The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics. Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs Obesity Therapeutics Assessment Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others. Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements Obesity Report Key Insights 1. Obesity Patient Population 2. Obesity Market Size and Trends 3. Key Cross Competition in the Obesity Market 4. Obesity Market Dynamics (Key Drivers and Barriers) 5. Obesity Market Opportunities 6. Obesity Therapeutic Approaches 7. Obesity Pipeline Analysis 8. Obesity Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Obesity Market Table of Contents 1. Key Insights 2. Executive Summary 3. Obesity Competitive Intelligence Analysis 4. Obesity Market Overview at a Glance 5. Obesity Disease Background and Overview 6. Obesity Patient Journey 7. Obesity Epidemiology and Patient Population 8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices 9. Obesity Unmet Needs 10. Key Endpoints of Obesity Treatment 11. Obesity Marketed Products 12. Obesity Emerging Therapies 13. Obesity Seven Major Market Analysis 14. Attribute Analysis 15. Obesity Market Outlook (7 major markets) 16. Obesity Access and Reimbursement Overview 17. KOL Views on the Obesity Market 18. Obesity Market Drivers 19. Obesity Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
Globe and Mail
an hour ago
- Globe and Mail
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
The right stocks can turbocharge your stock portfolio and set you up for a comfortable retirement. However, there are nuances to investing in growing companies. Sure, a home run stock can make you a millionaire on its own. However, if it were easy, there would be many more millionaires. The hit rate is low, so investors are usually better off looking for proven winners that still have plenty of life left in them. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The world's largest technology companies are driving ongoing growth trends, including e-commerce, digital advertising, and cloud computing. These same companies could also benefit from upcoming opportunities in artificial intelligence (AI). Investing $100,000 into each of these "Magnificent Seven" stocks as part of a diversified portfolio could yield a million dollars a decade from now. Here are their names, and why they could make you serious money well into the future. 1. Amazon E-commerce is Amazon 's (NASDAQ: AMZN) core business, and the carrot that draws consumers into its Prime membership and ecosystem. However, Amazon is just as much a technology company as any. It operates the world's leading cloud platform, Amazon Web Services, which holds an estimated 30% share of the global cloud infrastructure market. AWS is Amazon's cash cow, contributing over half of the company's total operating income despite representing just a fraction of its total revenue. That's especially important, given that AI is arguably the most prominent growth trend of the upcoming decade. AI, like most modern software, primarily runs on the cloud. AI applications are already driving significant growth for cloud capacity, prompting Amazon and other cloud companies to invest billions of dollars in building data centers to handle the load. Amazon's valuation, a PEG ratio of 2, is reasonable for its estimated 17% long-term earnings growth. In other words, the stock's investment returns should reflect that growth over time. If so, cloud tailwinds from AI should boost Amazon's most profitable business and could more than double earnings and the stock over the next decade. 2. Alphabet (Google) Most investors know Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) for Google Search, but it's a diversified tech giant. It owns YouTube, Android smartphone software, and Google Chrome, develops AI software and quantum computers, and continues to expand Waymo, a ride-hailing service using self-driving vehicles. Its massive size and broad reach make it highly likely that Alphabet will compete in AI and the opportunities it creates over the coming decade. Wall Street anticipates Alphabet growing its earnings by an average of 15% annually over the long term, despite some fears that AI chatbots could disrupt Google Search, Alphabet's core business. Investors shouldn't dismiss this risk, but fear has priced the stock at a compelling PEG ratio of 1.3, assuming the company meets Wall Street's growth estimates. If it does, investors could eventually see returns exceed Alphabet's growth if sentiment rebounds and drives the valuation higher. Alphabet's anticipated double-digit growth and depressed valuation make it a candidate for substantial returns over the next decade. 3. Meta Platforms Last but not least is Meta Platforms (NASDAQ: META), the parent company of social media apps such as Facebook, Instagram, WhatsApp, and Threads. The company is immensely profitable, generating $50 billion in free cash flow over the past four quarters from ads shown to the 3.43 billion people who use Meta's social apps each day. Meta Platforms still has firm long-term leadership; CEO and co-founder Mark Zuckerberg is still only 41 years old. He has been pushing the company toward AI for several years, using AI technology to optimize its core advertising business, and launching an open-sourced AI model with over a billion downloads, and is working to establish Meta Platforms as a key player in next-generation consumer electronics. Meta Platforms has rallied and is up significantly over the past few years. Yet the stock's PEG ratio (1.5) remains attractive for prospective investors, and Meta's estimated long-term earnings growth rate of 18% suggests there is enough upside for the stock to double or more over the coming decade. Meta Platforms must still monetize more of its AI projects, but if successful, investors will be glad they have this company in their portfolio over the next decade. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, and Meta Platforms. The Motley Fool has a disclosure policy.
